Ignite Creation Date:
2025-12-25 @ 12:28 AM
Ignite Modification Date:
2026-04-25 @ 12:47 PM
Study NCT ID:
NCT01164267
Status:
COMPLETED
Last Update Posted:
2013-11-25
First Post:
2010-07-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
Sponsor:
International Extranodal Lymphoma Study Group (IELSG)
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IELSG 34
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None